REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Four-membered And Includes At Least One Ring Nitrogen > Chalcogen Double Bonded Directly To A Ring Carbon Of The Four-membered Hetero Ring Which Is Adjacent To The Ring Nitrogen Chalcogen Double Bonded Directly To A Ring Carbon Of The Four-membered Hetero Ring Which Is Adjacent To The Ring NitrogenChalcogen Double Bonded Directly To A Ring Carbon Of The Four-membered Hetero Ring Which Is Adjacent To The Ring Nitrogen patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/14/06 - 20060281729 - Macrocyclic heterocyclic aspartyl protease inhibitors Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or ... 12/14/06 - 20060281728 - 3-substituted beta-lactamyl vasopressin v1a antagonists Novel 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof are described. Methods for using 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor are also described. ... 11/30/06 - 20060270652 - Benzimidazole-carboxamide compounds as 5-ht4, receptor agonists wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing ... 11/09/06 - 20060252742 - Therapeutic substituted beta-lactams or pharmaceutically acceptable salts or a prodrugs thereof are disclosed herein; wherein Y, A, X, J, and E are described herein. ... 10/19/06 - 20060234996 - Novel crystalline form of ezetimibe and processes for the preparation thereof A novel crystalline form of Ezetimibe and processes for the preparation thereof are disclosed. ... 09/28/06 - 20060217364 - Beta-lactamyl vasopressin v1a antagonists Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor. ... 09/28/06 - 20060217363 - Methods and therapeutic combinations for the treatment of hypercholesterolemia and xanthoma using sterol absorption inhibitors The present invention provides therapeutic combinations and methods including at least one sterol or 5α-stanol absorption inhibitor that can be useful for treating xanthomas and hypercholesterolemia. ... 09/14/06 - 20060205708 - Aryl oximes Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, ... 09/07/06 - 20060199793 - Sterol absorption inhibitor compounds The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. ... 07/20/06 - 20060160785 - Ezetimibe polymorphs Provided are processes for preparing crystalline forms of ezetimibe, such as ezetimibe Form A or Form B, for example, by precipitating ezetimibe from selected solvents. Alternatively, some forms may be transformed into different forms at elevated temperatures or under various humidity conditions, or by micronization. Also provided are micronized ezetimibe ... 03/30/06 - 20060069080 - Combinations of substituted azetidinones and cb1 antagonists The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols. ... 03/16/06 - 20060058283 - Compositions comprising ubiquinones The present invention provides antihyperlipidemic or antihypercholesterolemic compositions. These compositions ameliorate the adverse effects associated with other antihyperlipidemic or antihypercholesterolemic compositions. The present invention further provides methods of using the antihyperlipidemic or antihypercholesterolemic compositions. ... 02/02/06 - 20060025401 - Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders Inhibitors of the cellular sodium-dependent chloride/bicarbonate exchangers show an inhibiting effect on the secretion of von-Willebrand factor. These inhibitors can therefore be employed for the treatment of thrombotic and inflammatory disorders. ... 11/24/05 - 20050261270 - Modified beta-lactamases and uses thereof A tool that can screen bacteria for β-lactamases against a panel of various antibiotics is desirable. A biosensor incorporating an indicator molecule into β-lactamases may achieve this purpose, but it requires that the attached indicator molecule must not impair the binding affinity of the protein to a great extent to ... 10/27/05 - 20050239766 - Diphenylazetidinone derivatives for treating disorders of the lipid metabolism Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described. ... 08/04/05 - 20050171082 - Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same The present invention relates to highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using therefor. The invention involves a multi-step synthesis to produce the lactam compounds. In one step of the reaction sequence, asymmetric hydrogenation of a lactam-enamide was performed to produce an intermediate that can ... 08/04/05 - 20050171080 - Polymorphs of ezetimibe and process for preparation thereof The present invention relates to novel crystalline forms and amorphous form of Ezetimibe and the processes for the preparation thereof. ... 07/14/05 - 20050153952 - Methods for inhibiting sterol absorption The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols. ... 06/09/05 - 20050124598 - Antibiotic compounds The present invention provides methods for identifying monobactams with anti-PBP2a activity. The method involves the selection of RNA biocatalysts that promote the formation of monobactams with anti-PBP2a activity from component reactants. The invention also provides novel monobactams with anti-PBP2a activity identified by these methods. The invention also provides RNA biocatalysts ... ### FreshPatents.com Support |